Improve MEK/ERK targeting in mutant KRAS lung cancer

被引：0
|
作者：
Chen, Zhao [1 ]
Weisberg, Ellen [1 ]
Cheng, Katherine [1 ]
Kung, Andrew L. [2 ]
Bradner, James [1 ]
Griffin, James [1 ]
Wong, Kwok-Kin [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Columbia Univ, New York, NY USA
来源：
MOLECULAR CANCER RESEARCH | 2014年 / 12卷
关键词：
D O I：
10.1158/1557-3125.RASONC14-B01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B01
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities
    Zhang, Jun
    Park, Dongkyoo
    Shin, Dong M.
    Deng, Xingming
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2016, 48 (01) : 11 - 16
  • [32] KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
    Karimi, Nastaran
    Moghaddam, Seyed Javad
    CELLS, 2023, 12 (05)
  • [33] Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
    Uras, Iris Z.
    Moll, Herwig P.
    Casanova, Emilio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12) : 1 - 30
  • [34] Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma
    Vaseva, Angelina V.
    Bandyopadhyay, Abhik
    Del Pozo, Vanessa
    Goodwin, Craig M.
    Gautam, Prson
    Wennerberg, Krister
    Wood, Kris C.
    Chen, Yidong
    Der, Channing J.
    Houghton, Peter J.
    CANCER RESEARCH, 2020, 80 (14) : 72 - 72
  • [35] Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway
    Hu, Haoyue
    Liu, Yanyang
    Tan, Songtao
    Xie, Xiao Xiao
    He, Jun
    Luo, Feng
    Wang, Li
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3579 - 3587
  • [36] Differential Targeting of KRAS and BRAF Mutant Tumors Using MEK Inhibitors with Distinct Mechanisms of Action
    Hatzivassiliou, G.
    Haling, J.
    Chen, H.
    Song, K.
    Peck, A.
    Hoeflich, K.
    Friedman, L.
    Malek, S.
    Belvin, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 115 - 115
  • [37] Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC
    Rosell, Rafael
    Karachaliou, Niki
    Codony-Servat, Carles
    Ito, Masaoki
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S183 - S186
  • [38] Repotrectinib increases effectiveness of MEK inhibitors in KRAS mutant cancer models.
    Lee, Nathan V.
    Deng, Wei
    Zhai, Dayong
    Rodon, Laura
    Parra, Ana
    Cowell, Jessica
    Banisadr, Afsheen
    Zhang, Xin
    Murray, Brion W.
    CANCER RESEARCH, 2021, 81 (13)
  • [39] Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer
    Zhang, Peng
    Kawakami, Hisato
    Liu, Weizhen
    Zeng, Xiangyu
    Strebhardt, Klaus
    Tao, Kaixiong
    Huang, Shengbing
    Sinicrope, Frank A.
    MOLECULAR CANCER RESEARCH, 2018, 16 (03) : 378 - 389
  • [40] Targeting the ERK-MYC signaling network for the treatment of KRAS-mutant cancers
    Der, Channing J.
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
12345